Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 360, Issue 1461, 2005, Pages 1747-1767

  Blazar, Bruce R ^a   Murphy, William J ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic; Bone marrow transplantation; Cytokines; Graft versus leukaemia; Graft versus host disease

Indexed keywords

DISEASE TREATMENT; IMMUNE RESPONSE; MORBIDITY; TRANSPLANTATION;

CYTOKINE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MOUSE; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; MICE; MODELS, IMMUNOLOGICAL; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33644821494     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2005.1701     Document Type: Review

References (234)

1. Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H. & Honjo, T. 1996 Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772.
2. Aicher, A., Hayden-Ledbetter, M., Brady, W. A., Pezzutto, A., Richter, G., Magaletti, D., Buckwalter, S., Ledbetter, J. A. & Clark, E. A. 2000 Characterization of human inducible costimulator ligand expression and function. J. Immunol. 164, 4689-4696.
3. Akiba, H. et al. 2000 Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191, 375-380. (doi:10.1084/jem.191.2.375.)
4. Albert, M. H., Yu, X. Z., Martin, P. J. & Anasetti, C. 2005 Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood 105, 1355-1361. (doi:10.1182/blood-2004-08-3305.)
5. Alderson, M. R. et al. 1994 Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24, 2219-2227.
6. Almenara, J., Rosato, R. & Grant, S. 2002 Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16, 1331-1343. (doi:10.1038/sj.leu.2402535.)
7. Alpdogan, O., Schmaltz, C., Muriglan, S. J., Kappel, B. J., Perales, M. A., Rotolo, J. A., Halm, J. A., Rich, B. E. & van den Brink, M. R. 2001 Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98, 2256-2265. (doi:10.1182/blood.V98.7.2256.)
8. Amakawa, R. et al. 1996 Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84, 551-562. (doi:10.1016/S0092-8674(00)81031-4.)
9. Amrolia, P. J. et al. 2003 Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102, 2292-2299. (doi:10.1182/blood-2002-11-3516.)
10. Anderson, B. E., McNiff, J., Yan, J., Doyle, H., Mamula, M., Shlomchik, M. J. & Shlomchik, W. D. 2003 Memory CD4+ T cells do not induce graft-versus-host disease. J. Clin. Invest. 112, 101-108. (doi:10.1172/ JCI200317601.)
11. Anderson, B. E., McNiff, J. M., Jain, D., Blazar, B. R., Shlomchik, W. D. & Shlomchik, M. J. 2005 Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105, 2227-2234. (doi:10.1182/blood-2004-08-3032.)
12. Asai, O., Longo, D. L., Tian, Z. G., Hornung, R. L., Taub, D. D., Ruscetti, F. W. & Murphy, W. J. 1998 Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Invest. 101, 1835-1842.
13. Bacchetta, R., Zappone, E., Zino, E., Fleischhauer, K., Blazar, B., Narula, S., Bordignon, C. & Roncarolo, M. G. 2000 Use of IL-10 anergized T cells in haploidentical bone marrow transplantation. Blood 96, 580a.
14. Baecher-Allan, C., Brown, J. A., Freeman, G. J. & Hafler, D. A. 2001 CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167, 1245-1253.
15. Bansal-Pakala, P., Jember, A. G. & Croft, M. 2001 Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7, 907-912. (doi:10.1038/90942.)
16. Baum, P. R. et al. 1994a Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 13, 3992-4001.
17. Baum, P. R. et al. 1994b Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor. Circ. Shock 44, 30-34.
18. Billiau, A. D., Fevery, S., Rutgeerts, O., Landuyt, W. & Waer, M. 2003 Transient expansion of Mac1+Ly6-G+ Ly6-C+ early myeloid cells widi suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood 102, 740-748. (doi:10.1182/blood-2002-06-1833. )
19. Birkeland, M. L., Copeland, N. G., Gilbert, D. J., Jenkins, N. A. & Barclay, A. N. 1995 Gene structure and chromosomal localization of the mouse homologue of rat OX40 protein. Eur. J. Immunol. 25, 926-930.
20. Blazar, B. R., Taylor, P. A., Linsley, P. S. & Vallera, D. A. 1994 In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83, 3815-3825.
21. Blazar, B. R., Taylor, P. A., Panoskaltsis-Mortari, A., Gray, G. S. & Vallera, D. A. 1995a Coblockade of the LFA1: ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85, 2607-2618.
22. Blazar, B. R., Taylor, P. A., Smith, S. & Vallera, D. A. 1995b Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 85, 842-851.
23. Blazar, B. R., Sharpe, A. H., Taylor, P. A., Panoskaltsis-Mortari, A., Gray, G. S., Korngold, R. & Vallera, D. A. 1996 Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. J. Immunol. 157, 3250-3259.
24. Blazar, B. R., Taylor, P. A., Panoskaltsis-Mortari, A., Buhlman, J., Xu, J., Flavell, R. A., Korngold, R., Noelle, R. & Vallera, D. A. 1997 Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J. Immunol. 158, 29-39.
25. Blazar, B. R., Taylor, P. A., Noelle, R. J. & Vallera, D. A. 1998 CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J. Clin. Invest. 102, 473-482.
26. Blazar, B. R., Taylor, P. A., Panoskaltsis-Mortari, A., Sharpe, A. H. & Vallera, D. A. 1999 Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 162, 6368-6377.
27. Blazar, B. R., Kwon, B. S., Panoskaltsis-Mortari, A., Kwak, K. B., Peschon, J. J. & Taylor, P. A. 2001a Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J. Immunol. 166, 3174-3183.
28. Blazar, B. R., McKenna, H. J., Panoskaltsis-Mortari, A. & Taylor, P. A. 2001b Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality. Biol. Blood Marrow Transplant. 7, 197-207. (doi:10.1053/bbmt.2001.v7.pm11349806.)
29. Blazar, B. R., Carreno, B., Panoskaltsis-Mortari, A., Carter, L., Iwai, Y., Yagita, H., Nishimura, H. & Taylor, P. A. 2002 PD-1 engagement provides an inhibitory signal which downregulates T cell alloresponses in vivo. Blood 100, 72a. (doi:10.1182/blood.V100.1.72.)
30. Blazar, B. R., Sharpe, A. H., Chen, A. I., Panoskaltsis-Mortari, A., Lees, C., Akiba, H., Yagita, H., Killeen, N. & Taylor, P. A. 2003 Ligation of OX40 (CD 134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 101, 3741-3748. (doi:10.1182/blood-2002-10-3048.)
31. Boussiotis, V. A., Chen, Z. M., Zeller, J. C., Murphy, W. J., Berezovskaya, A., Narula, S., Roncarolo, M. G. & Blazar, B. R. 2001 Altered T-cell receptor+CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-beta-treated alloreactive T cells that do not induce graft-versus-host disease. Blood 97, 565-571. (doi:10.1182/blood.V97.2.565.)
32. Bowen, M. A., Lee, R. K., Miragliotta, G., Nam, S. Y. & Podack, E. R. 1996 Structure and expression of murine CD30 and its role in cytokine production. J. Immunol. 156, 442-449.
33. Brocker, T., Gulbranson-Judge, A., Flynn, S., Riedinger, M., Raykundalia, C. & Lane, P. 1999 CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur. J. Immunol. 29, 1610-1616. (doi:10.1002/(SICI)1521-4141(199905) 29:05〈1610::AID- IMMU1610〉3.0.CO;2-8.)
34. Bross, P. F. et al. 2004 Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 10, 3954-3964.
35. Brown, G. R., Lee, E. & Thiele, D. L. 2002 TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J→C57BL/6JXbm12)F1 mice. J. Immunol. 168, 3065-3071.
36. Buhlmann, J. E., Gonzalez, M., Ginther, B., Panoskaltsis-Mortari, A., Blazar, B. R., Greiner, D. L., Rossini, A. A., Flavell, R. & Noelle, R. J. 1999 Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J. Immunol. 162, 4373-4376.
37. Butler, L. M. et al. 2000 Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165-5170.
38. Calderhead, D. M., Buhlmann, J. E., van den Eertwegh, A. J., Claassen, E., Noelle, R. J. & Fell, H. P. 1993 Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J. Immunol. 151, 5261-5271.
39. Chan, K. W., Hopke, C. D., Krams, S. M. & Martinez, O. M. 2002 CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses. J. Immunol. 169, 1784-1791.
40. Chen, A. I. et al. 1999 Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 11, 689-698. (doi:10.1016/81074- 7613(00) 80143-0.)
41. Chen, B. J., Cui, X., Liu, C. & Chao, N. J. 2002 Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99, 3083-3088. (doi:10.1182/blood.V99.9.3083.)
42. Chen, Z. M., O'Shaughnessy, M. J., Gramaglia, I., Panoskaltsis-Mortari, A., Murphy, W. J., Narula, S., Roncarolo, M. G. & Blazar, B. R. 2003 IL-10 and TGF-beta induce alloreactive CD4+ CD25- T cells to acquire regulatory cell function. Blood 101, 5076-5083. (doi:10.1182/blood-2002-09-2798.)
43. Chen, B. J., Cui, X., Sempowski, G. D., Liu, C. & Chao, N. J. 2004 Transfer of allogeneic CD62L-memory T cells without graft-versus-host disease. Blood 103, 1534-1541. (doi:10.1182/blood-2003-08-2987.)
44. Chiarle, R., Podda, A., Prolla, G., Podack, E. R., Thorbecke, G. J. & Inghirami, G. 1999 CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J. Immunol. 163, 194-205.
45. Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M. & Hoshino, Y. 1998 FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160, 5037-5044.
46. Cohen, J. L., Trenado, A., Vasey, D., Klatzmann, D. & Salomon, B. L. 2002a CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196, 401-406. (doi:10.1084/jem.20020090. )
47. Cohen, L. A., Marks, P. A., Rifkind, R. A., Amin, S., Desai, D., Pittman, B. & Richon, V. M. 2002b Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res. 22, 1497-1504.
48. Coyle, A. J. & Gutierrez-Ramos, J. C. 2001 The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. 2, 203-209. (doi:10.1038/85251.)
49. Coyle, A. J. et al. 2000 The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13, 95-105. (doi:10.1016/81074-7613(00) 00011-X.)
50. Davies, S. M., Ruggieri, L., DeFor, T., Wagner, J. E., Weisdorf, D. J., Miller, J. S., Velardi, A. & Blazar, B. R. 2002 Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100, 3825-3827. (doi:10.1182/blood-2002-04- 1197.)
51. DeBenedette, M. A., Shahinian, A., Mak, T. W. & Watts, T. H. 1997 Costimulation of CD28- T lymphocytes by 4-1BB ligand. J. Immunol. 158, 551-559.
52. DeBenedette, M. A., Wen, T., Bachmann, M. F., Ohashi, P. S., Barber, B. H., Stocking, K. L., Peschon, J. J. & Watts, T. H. 1999 Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J. Immunol. 163, 4833-4841.
53. De Smedt, T., Smith, J., Baum, P., Fanslow, W., Butz, E. & Maliszewski, C. 2002 Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168, 661-670.
54. Dieckmann, D., Plottner, H., Berchtold, S., Berger, T. & Schuler, G. 2001 Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 193, 1303-1310. (doi:10.1084/jem.193.11.1303.)
55. Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S. & Gianni, A. M. 2002 Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843. (doi:10.1182/blood.V99.10.3838.)
56. Dong, H., Zhu, G., Tamada, K. & Chen, L. 1999 B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365-1369. (doi:10.1038/70932.)
57. Dong, C., Juedes, A. E., Temann, U. A., Shresta, S., Allison, J. P., Ruddle, N. H. & Flavell, R. A. 2001 ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409, 97-101. (doi:10.1038/35051100.)
58. Duckett, C. S. & Thompson, C. B. 1997 CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 11, 2810-2821.
59. Duffher, U. et al. 2003 Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp. Hematol. 31, 897-902. (doi:10.1016/S0301-472X(03)00198-X.)
60. Durkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B. & Stein, H. 1992 Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68, 421-427.
61. Edinger, M., Hoffman, P., Ermann, J., Drago, K., Fathman, C. G., Strober, S. S. & Negrin, R. S. 2003 CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9, 1144-1150. (doi:10.1038/nm915.)
62. Evans, D. E., Prell, R. A., Thalhofer, C. J., Hurwitz, A. A. & Weinberg, A. D. 2001 Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J. Immunol. 167, 6804-6811.
63. Flynn, S., Toellner, K. M., Raykundalia, C., Goodall, M. & Lane, P. 1998 CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188, 297-304. (doi:10.1084/jem.188.2.297.)
64. Foster, A. E., Marangolo, M., Sartor, M. M., Alexander, S. I., Hu, M., Bradstock, K. F. & Gottlieb, D. J. 2004 Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 104, 2403-2409. (doi:10.1182/blood-2003-12-4431.)
65. Freeman, G. J. et al. 2000 Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034. (doi:10.1084/jem.192.7.1027.)
66. Gendelman, M., Hecht, T., Logan, B., Vodanovic-Jankovic, S., Komorowski, R. & Drobyski, W. R. 2004 Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. J. Immunol. 172, 3328-3336.
67. Ghansah, T. et al. 2004 Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J. Immunol. 173, 7324-7330.
68. Giralt, S., Aleman, A., Lei, X., Davis, M., Mickler, K., Weber, D., Wang, M. & Champlin, R. 2004 Results of bortezomib (BTZ) therapy for myeloma (MM) patients relapsing after an allogeneic transplant. Preliminary results show efficacy without induction of GVHD. Blood 104, 459a.
69. Godfrey, W. R., Krampf, M. R., Taylor, P. A. & Blazar, B. R. 2004 Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 103, 1158-1165. (doi:10.1182/blood-2003-04-1098.)
70. Godfrey, W. R., Spoden, D. J., Ge, Y. G., Baker, S. R., Liu, B., Levine, B. L., June, C. H., Blazar, B. R. & Porter, S. B. 2005 Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 105, 750-758. (doi:10.1182/blood-2004-06- 2467.)
71. Gonzalo, J. A., Delaney, T., Corcoran, J., Goodearl, A., Gutierrez-Ramos, J. C. & Coyle, A. J. 2001a Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation. J. Immunol. 166, 1-5.
72. Gonzalo, J. A. et al. 2001b ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat. Immunol. 2, 597-604. (doi:10.1038/89739.)
73. Goodwin, R. G. et al. 1993 Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 23, 2631-2641.
74. Gramaglia, I., Weinberg, A. D., Lemon, M. & Croft, M. 1998 Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161, 6510-6517.
75. Gramaglia, I., Jember, A., Pippig, S. D., Weinberg, A. D., Killeen, N. & Croft, M. 2000 The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165, 3043-3050.
76. Guinan, E. C., Boussiotis, V. A., Neuberg, D., Brennan, L. L., Hirano, N., Nadler, L. M. & Gribben, J. G. 1999 Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340, 1704-1714. (doi:10.1056/NEJM199906033402202.)
77. Hakim, F. T., Cepeda, R., Gray, G. S., June, C. H. & Abe, R. 1995 Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. J. Immunol. 155, 1757-1766.
78. Hanash, A. M. & Levy, R. B. 2005 Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 105, 1828-1836. (doi:10.1182/blood-2004-08-3213.)
79. Hashimoto, D., Asakura, S., Miyake, S., Yamamura, T., Van Kaer, L., Liu, C., Tanimoto, M. & Teshima, T. 2005 Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol. 174, 551-556.
80. Hildebrandt, G. C., Olkiewicz, K. M., Choi, S., Corrion, L. A., Clouthier, S. G., Liu, C., Serody, J. S. & Cooke, K. R. 2004 Donor T cell-production of RANTES significantly contributes to the development of Idiopathic Pneumonia Syndrome after allogeneic stem cell transplantation. Blood 105, 2249-2257. (doi:10.1182/blood-2004-08-3320.)
81. Hoffmann, P., Ermann, J., Edinger, M., Fathman, C. G. & Strober, S. 2002a Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196, 389-399. (doi:10.1084/jem.20020399.)
82. Hoffman, P., Ermann, J., Edinger, M., Fathman, C. G. & Strober, S. 2002b Donor-type CD4(+)CD25(+) regula-tory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow trnasplantation. J. Exp. Med. 196, 389-399.
83. Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R. & Edinger, M. 2004 Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 104, 895-903. (doi:10.1182/blood-2004- 01-0086.)
84. Hurtado, J. C., Kim, S. H., Pollok, K. E., Lee, Z. H. & Kwon, B. S. 1995 Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J. Immunol. 155, 3360-3367.
85. Hurtado, J. C., Kim, Y. J. & Kwon, B. S. 1997 Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158, 2600-2609.
86. Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I. & Kroczek, R. A. 1999 ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397, 263-266. (doi:10.1038/16717.)
87. Imado, T., Iwasaki, T., Kataoka, Y., Kuroiwa, T., Hara, H., Fujimoto, J. & Sano, H. 2004 Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation. Blood 104, 1542-1549. (doi:10.1182/blood-2003-12-4309.)
88. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. 1992 Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887-3895.
89. Jarvinen, L. Z., Blazar, B. R., Adeyi, O. A., Strom, T. B. & Noelle, R. J. 2003 CD154 on the surface of CD4+ CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation 76, 1375-1379. (doi:10.1097/01.TP. 0000093462.16309.73.)
90. Joffre, O., Gorsse, N., Romagnoli, P. & van Meerwijk, J. P. 2004 Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood 103, 4216-4221. (doi:10.1182/blood-2004-01-0005.)
91. Jones, S. C., Murphy, G. F. & Korngold, R. 2003 Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol. Blood Marrow Transplant. 9, 243-256. (doi:10.1053/bbmt.2003.50027.)
92. Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J. & Enk, A. H. 2001 Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193, 1285-1294. (doi:10.1084/jem.193.11.1285.)
93. Jonuleit, H., Schmitt, E., Kakirman, H., Stassen, M., Knop, J. & Enk, A. H. 2002 Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J. Exp. Med. 196, 255-260. (doi:10.1084/jem.20020394.)
94. Jung, U., Foley, J. E., Erdmann, A. A., Eckhaus, M. A. & Fowler, D. H. 2003 CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 102, 3439-3446. (doi:10.1182/blood-2002-12-3936.)
95. Kane, R. C., Bross, P. F., Farrell, A. T. & Pazdur, R. 2003 Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8, 508-513. (doi:10.1634/theoncologist.8-6-508.)
96. Khayyamian, S., Hutloff, A., Buchner, K., Grafe, M., Henn, V., Kroczek, R. A. & Mages, H. W. 2002 ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc. Natl Acad. Sci. USA 99, 6198-6203. (doi:10.1073/pnas.092576699.)
97. Kim, Y. M., Sachs, T., Asavaroengchai, W., Bronson, R. & Sykes, M. 2003 Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J. Clin. Invest. 111, 659-669. (doi:10.1172/JCI200316950.)
98. Kingsbury, G. A. et al. 2001 Cloning, expression, and function of BLAME, a novel member of the CD2 family. J. Immunol. 166, 5675-5680.
99. Koehl, U. et al. 2004 IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol. Dis. 33, 261-266. (doi:10.1016/j.bcmd.2004.08.013.)
100. Koh, M. B., Prentice, H. G., Corbo, M., Morgan, M., Cotter, F. E. & Lowdell, M. W. 2002 Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br. J. Haematol. 118, 108-116. (doi:10.1046/j.1365-2141.2002.03682.x.)
101. Kopf, M., Ruedl, C., Schmitz, N., Gallimore, A., Lefrang, K., Ecabert, B., Odermatt, B. & Bachmann, M. F. 1999 OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 11, 699-708. (doi:10.1016/S1074-7613(00)80144-2. )
102. Kopf, M., Coyle, A. J., Schmitz, N., Barner, M., Oxenius, A., Gallimore, A., Gutierrez-Ramos, J. C. & Bachmann, M. F. 2000 Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J. Exp. Med. 192, 53-61. (doi:10.1084/jem.192.1.53.)
103. Korngold, R., Marini, J. C., de Baca, M. E., Murphy, G. F. & Giles-Komar, J. 2003 Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol. Blood Marrow Transplant. 9, 292-303. (doi:10.1016/S1083-8791(03)00087-9.)
104. Kreisel, D. et al. 2002 Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat. Med. 8, 233-239. (doi:10.1038/nm0302-233.)
105. Krijanovski, O. I., Hill, G. R., Cooke, K. R., Teshima, T., Crawford, J. M., Brinson, Y. S. & Ferrara, J. L. 1999 Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 94, 825-831.
106. Kuroiwa, T. et al. 2001 Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J. Clin. Invest. 107, 1365-1373.
107. Kurts, C., Carbone, F. R., Krummel, M. F., Koch, K. M., Miller, J. F. & Heath, W. R. 1999 Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 398, 341-344. (doi:10.1038/18692.)
108. Kwon, B. S. & Weissman, S. M. 1989 cDNA sequences of two inducible T-cell genes. Proc. Natl Acad. Sci. USA 86, 1963-1967.
109. Latchman, Y. et al. 2001 PD-L2 is a second ligand for PD-I and inhibits T cell activation. Nat. Immunol. 2, 261-268. (doi:10.1038/85330.)
110. Latza, U., Durkop, H., Schnittger, S., Ringeling, J., Eitelbach, F., Hummel, M., Fonatsch, C. & Stein, H. 1994 The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur. J. Immunol. 24, 677-683.
111. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E. & Ringden, O. 2003 HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31, 890-896. (doi:10.1016/S0301-472X(03)00110-3.)
112. Lee, R. S., Kuhr, C. S., Sale, G. E., Zellmer, E., Hogan, W. J., Storb, R. & Little, M. T. 2003 FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model. Transplantation 76, 1155-1158. (doi:10.1097/01.TP.0000083891.14089.B8.)
113. Leoni, F. et al. 2002 The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl Acad. Sci. USA 99, 2995-3000. (doi:10.1073/pnas.052702999.)
114. Levings, M. K., Sangregorio, R. & Roncarolo, M. G. 2001 Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193, 1295-1302. (doi:10.1084/jem.193.11.1295.)
115. Li, Y., Li, X. C., Zheng, X. X., Wells, A. D., Turka, L. A. & Strom, T. B. 1999 Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5, 1298-1302. (doi:10.1038/15256.)
116. Li, B., New, J. Y., Yap, E. H., Lu, J., Chan, S. H. & Hu, H. 2001 Blocking L-selectin and alpha4-integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease. Eur. J. Immunol. 31, 617-624. (doi:10.1002/1521-4141(200102)31:2〈617::AID-IMMU617〉3.3.CO;2- 4.)
117. Li, B., New, J. Y., Tay, Y. K., Goh, E., Yap, E. H., Chan, S. H. & Hu, H. Z. 2004 Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at 1-selectin and alpha4-integrin prior to infusion. Scand J. Immunol. 59, 464-468. (doi:10.1111/j.0300-9475.2004.01414.x.)
118. Ling, V. et al. 2000 Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J. Immunol. 164, 1653-1657.
119. Ling, V., Wu, P. W., Miyashiro, J. S., Marusic, S., Finnerty, H. F. & Collins, M. 2001 Differential expression of inducible costimulator-ligand splice variants: lymphoid regulation of mouse GL50-B and human GL50 molecules. J. Immunol. 166, 7300-7308.
120. Mallett, S., Possum, S. & Barclay, A. N. 1990 Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. EMBO J. 9, 1063-1068.
121. Martinez, O. M., Villanueva, J., Abtahi, S., Beatty, P. R., Esquivel, C. O. & Krams, S. M. 1998 CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 65, 1240-1247. (doi:10.1097/00007890- 199805150-00016.)
122. Matte, C. C., Liu, J., Cormier, J., Anderson, B. E., Athanasiadis, I., Jain, D., McNiff, J. & Shlomchik, W. D. 2004 Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10, 987-992. (doi:10.1038/nm1089.)
123. McAdam, A. J. et al. 2000 Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4(+) T cells. J. Immunol 165, 5035-5040.
124. McAdam, A. J., Greenwald, R. J., Levin, M. A., Chernova, T., Malenkovich, N., Ling, V., Freeman, G. J. & Sharpe, A. H. 2001 ICOS is critical for CD40-mediated antibody class switching. Nature 409, 102-105. (doi:10.1038/35051107.)
125. Meisel, R., Zibert, A., Laryea, M., Gobel, U., Daubener, W. & Dilloo, D. 2004 Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619-4621. (doi:10.1182/blood-2003-11-3909.)
126. Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S. & Chen, L. 1998 NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 190, 167-172. (doi:10.1006/cimm.1998.1396.)
127. Merad, M. et al. 2004 Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat. Med. 10, 510-517. (doi:10.1038/nm1038.)
128. Min, D., Taylor, P. A., Panoskaltsis-Mortari, A., Chung, B., Danilenko, D. M., Farrell, C., Lacey, D. L., Blazar, B. R. & Weinberg, K. I. 2002 Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 99, 4592-4600. (doi:10.1182/blood.V99.12.4592.)
129. Min, C. K., Maeda, Y., Lowler, K., Liu, C., Clouthier, S., Lofthus, D., Weisiger, E., Ferrara, J. L. & Reddy, P. 2004 Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood 104, 3393-3399. (doi:10. 1182/blood-2004-02-0763.)
130. Montagna, D., Yvon, E., Calcaterra, V., Comoli, P., Locatelli, F., Maccario, R., Fisher, A. & Cavazzana-Calvo, M. 1999 Depletion of alloreactive T cells by a specific antiinterleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 93, 3550-3557.
131. Moser, B., Wolf, M., Walz, A. & Loetscher, P. 2004 Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25, 75-84. (doi:10.1016/j.it.2003.12.005.)
132. Murai, M., Yoneyama, H., Harada, A., Yi, Z., Vestergaard, C., Guo, B., Suzuki, K., Asakura, H. & Matsushima, K. 1999 Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104, 49-57.
133. Murai, M. et al. 2003 Peyer's patch is the essential site in initiating
134. Murata, K., Ishii, N., Takano, H., Miura, S., Ndhlovu, L. C., Nose, M., Noda, T. & Sugamura, K. 2000 Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 191, 365-374. (doi:10.1084/jem.191.2.365.)
135. Murphy, P. M. 2002 International union of pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev. 54, 227-229. (doi:10.1124/pr.54.2.227.)
136. Murphy, W. J. et al. 1998 Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J. Clin. Invest. 102, 1742-1748.
137. Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J. & Power, C. A. 2000 International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176.
138. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. 1999 Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151. (doi:10.1016/S1074-7613(00)80089-8.)
139. Nozawa, K., Ohata, J., Sakurai, J., Hashimoto, H., Miyajima, H., Yagita, H., Okumura, K. & Azuma, M. 2001 Preferential blockade of CD8(+) T cell responses by administration of anti-CD 137 ligand monoclonal anti-body results in differential effect on development of murine acute and chronic graft-versus-host diseases. J. Immunol. 167, 4981-4986.
140. Ohshima, Y., Tanaka, Y., Tozawa, H., Takahashi, Y., Maliszewski, C. & Delespesse, G. 1997 Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 159, 3838-3848.
141. Ohshima, Y., Yang, L. P., Uchiyama, T., Tanaka, Y., Baum, P., Sergerie, M., Hermann, P. & Delespesse, G. 1998 OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 92, 3338-3345.
142. O'Shaughnessy, M. J., Chen, Z.-m., Panoskaltsis-Mortari, A., Taub, D, Palmer, E., Berg, L. A., Murphy, W. I. & Blazar, B. R. Submitted. Ex vivo blockade of the Janus kinase 3 pathway in alloreactive T Cells abolishes their capacity to induce murine graft versus host disease. Blood.
143. Panoskaltsis-Mortari, A., Taylor, P. A., Rubin, J. S., Uren, A., Welniak, L. A., Murphy, W. J., Farrell, C. L., Lacey, D. L. & Blazar, B. R. 2000 Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 96, 4350-4356.
144. Panoskaltsis-Mortari, A., Hermanson, J. R., Taras, E., Wangensteen, O. D., Serody, J. S. & Blazar, B. R. 2003 Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood 101, 3714-3721. (doi:10.1182/blood-2002-08-2465.)
145. Petrovic, A. et al. 2004 LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 103, 1542-1547. (doi:10.1182/blood-2003-03- 0957.)
146. Pippig, S. D. et al. 1999 Robust B cell immunity but impaired T cell proliferation in the absence of CD 134 (OX40). J. Immunol. 163, 6520-6529.
147. Pollok, K. E., Kim, Y. J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T. & Kwon, B. S. 1993 Inducible T cell antigen 4-1BB. Analysis of expression and function. J. Immunol. 150, 771-781.
148. Pollok, K. E., Kim, Y. J., Hurtado, J., Zhou, Z., Kim, K. K. & Kwon, B. S. 1994 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur. J. Immunol. 24, 367-374.
149. Potian, J. A., Aviv, H., Ponzio, N. M., Harrison, J. S. & Rameshwar, P. 2003 Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 171, 3426-3434.
150. Rao, A. R. et al. 2003 CC chemokine receptor 2 expression in donor cells serves an essential role in graft-versus-host-disease. J. Immunol. 171, 4875-4885.
151. Reddy, P., Teshima, T., Kukuruga, M., Ordemann, R., Liu, C., Lowler, K. & Ferrara, J. L. 2001 Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194, 1433-1440. (doi:10.1084/jem.194.10.1433.)
152. Reddy, P., Teshima, T., Hildebrandt, G., Williams, D. L., Liu, C., Cooke, K. R. & Ferrara, J. L. 2003 Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 101, 2877-2885. (doi:10.1182/blood-2002-08- 2566.)
153. Reddy, P., Maeda, Y., Hotary, K., Liu, C., Reznikov, L. L., Dinarello, C. A. & Ferrara, J. L. 2004 Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA 101, 3921-3926. (doi:10.1073/pnas.0400380101.)
154. Rogers, P. R. & Croft, M. 2000 CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen. J. Immunol. 164, 2955-2963.
155. Rogers, P. R., Song, J., Gramaglia, I., Killeen, N. & Croft, M. 2001 OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15, 445-455. (doi:10.1016/S1074-7613(01)00191- 1.)
156. Rollins, B. J. 1997 Chemokines. Blood 90, 909-928.
157. Rossi, S., Blazar, B. R., Farrell, C. L., Danilenko, D. M., Lacey, D. L., Weinberg, K. I., Krenger, W. & Hollander, G. A. 2002 Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 100, 682-691. (doi:10.1182/blood. V100.2.682.)
158. Ruggeri, L. et al. 2002 Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100. (doi:10.1126/science.1068440.)
159. Saito, K., Sakurai, J., Ohata, J., Kohsaka, T., Hashimoto, H., Okumura, K., Abe, R. & Azuma, M. 1998 Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J. Immunol. 160, 4225-4231.
160. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. 1995 Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164.
161. Sakaguchi, S. et al. 2001 Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18-32. (doi:10.1034/j.1600-065X.2001.1820102.x.)
162. Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. & Bluestone, J. A. 2000 B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440. (doi:10.1016/S1074-7613(00)80195-8.)
163. Saoulli, K. et al. 1998 CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187, 1849-1862. (doi:10.1084/jem.187.11.1849.)
164. Sayers, T. J. et al. 2003 The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102, 303-310. (doi:10.1182/blood-2002-09-2975.)
165. Shanebeck, K. D., Maliszewski, C. R., Kennedy, M. K., Picha, K. S., Smith, C. A., Goodwin, R. G. & Grabstein, K. H. 1995 Regulation of murine B cell growth and differentiation by CD30 ligand. Eur. J. Immunol. 25, 2147-2153.
166. Sharpe, A. H. & Freeman, G. J. 2002 The B7-CD28 superfamily. Nat. Rev. Immunol. 2, 116-126. (doi:10.1038/nri727.)
167. Shevach, E. M. 2001 Certified professionals: CD4(+) CD25(+) suppressor T cells. J. Exp. Med. 193, F41-F46. (doi:10.1084/jem.193.11.F41.)
168. Shevach, E. M. 2002 CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-100.
169. Shevach, E. M., McHugh, R. S., Piccirillo, C. A. & Thornton, A. M. 2001 Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol. Rev. 182, 58-67. (doi:10.1034/j.1600-065X.2001.1820104.x.)
170. Shimozato, O., Takeda, K., Yagita, H. & Okumura, K. 1999 Expression of CD30 ligand (CD153) on murine activated T cells. Biochem. Biophys. Res. Commun. 256, 519-526. (doi:10.1006/bbrc.1999.0336.)
171. Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M. & Honjo, T. 1994 Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 23, 704-706. (doi:10.1006/geno.1994.1562.)
172. Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J. & Emerson, S. G. 1999 Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412-415. (doi:10.1126/science.285.5426.412.)
173. Shuford, W. W. et al. 1997 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186, 47-55. (doi:10.1084/jem.186.1.47.)
174. Sinha, M. L., Fry, T. J., Fowler, D. H., Miller, G. & Mackall, C. L. 2002 Interleukin 7 worsens graft-versus-host disease. Blood 100, 2642-2649. (doi:10.1182/blood-2002-04-1082.)
175. Solomon, S. R. et al. 2002 Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 4, 395-406. (doi:10.1080/146532402320775982.)
176. Speiser, D., Bachmann, M., Frick, T., McKall-Faienza, K., Griffiths, E., Pfeffer, K., Mak, T. & Ohashi, P. 1997 TNF receptor p55 controls early acute graft-versus-host disease. J. Immunol. 158, 5185-5190.
177. Sperling, A. I. & Bluestone, J. A. 2001 ICOS costimulation: it's not just for TH2 cells anymore. Nat. Immunol. 2, 573-574. (doi:10.1038/89709.)
178. Spielberger, R. et al. 2004 Palifermin for oral mucostitis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351, 2590-2598. (doi:10.1056/NEJMoa040125.)
179. Stuber, E., Neurath, M., Calderhead, D., Fell, H. P. & Strober, W. 1995 Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2, 507-521. (doi:10.1016/1074-7613(95)90031-4.)
180. Sun, K. et al. 2004 Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl Acad. Sci. USA 101, 8120-8125. (doi:10.1073/pnas.0401563101.)
181. Sun, K., Wilkins, D. E., Anver, M. R., Sayers, T. J., Panoskaltsis-Mortari, A., Blazar, B. R., Welniak, L. A. & Murphy, W. J. 2005 Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GHVD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood. Published online 16 June 2005.
182. Suri-Payer, E., Amar, A. Z., Thornton, A. M. & Shevach, E. M. 1998 CD4+ CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160, 1212-1218.
183. Swallow, M. M., Wallin, J. J. & Sha, W. C. 1999 B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 11, 423-432. (doi:10.1016/S1074-7613(00)80117-X.)
184. Sykes, M., Romick, M. L. & Sachs, D. H. 1990 Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc. Natl Acad. Sci. USA 87, 5633-5637.
185. Sykes, M., Szot, G. L., Nguyen, P. L. & Pearson, D. A. 1995 Interleukin-12 inhibits murine graft-versus-host disease. Blood 86, 2429-2438.
186. Sykes, M., Pearson, D. A., Taylor, P. A., Szot, G. L., Goldman, S. J. & Blazar, B. R. 1999 Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. Biol. Blood Marrow Transplant. 5, 277-284.
187. Tafuri, A. et al. 2001 ICOS is essential for effective T-helper-cell responses. Nature 409, 105-109. (doi:10.1038/35051113.)
188. Takahashi, C., Mittler, R. S. & Vella, A. T. 1999 Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162, 5037-5040.
189. Tamura, H., Dong, H., Zhu, G., Sica, G. L., Flies, D. B., Tamada, K. & Chen, L. 2001 B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97, 1809-1816. (doi:10.1182/blood.V97.6.1809.)
190. Tan, J. T., Whitmire, J. K., Ahmed, R., Pearson, T. C. & Larsen, C. P. 1999 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J. Immunol. 163, 4859-4868.
191. Tan, J. T., Ha, J., Cho, H. R., Tucker-Burden, C., Hendrix, R. C., Mittler, R. S., Pearson, T. C. & Larsen, C. P. 2000 Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses. Transplantation 70, 175-183.
192. Tanaka, T., Ohtsuka, Y., Yagita, H., Shiratori, Y., Omata, M. & Okumura, K. 1995 Involvement of alpha 1 and alpha 4 integrins in gut mucosal injury of graft-versus-host disease. Int. Immunol. 7, 1183-1189.
193. Taylor, P. A., Panoskaltsis-Mortari, A., Noelle, R. J. & Blazar, B. R. 2000 Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody. J. Immunol. 164, 612-622.
194. Taylor, P. A., Lees, C. J., Allison, J. P., Fournier, S., Sharpe, A. H. & Blazar, B. R. 2001a B7 expression on T cells downregulates GVHD generation independent of CD4+ CD25+ immune regulatory T cells. Blood 98, 776a.
195. Taylor, P. A., Noelle, R. J. & Blazar, B. R. 2001b CD4(+) CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 193, 1311-1318. (doi:10.1084/jem.193. 11.1311.)
196. Taylor, P. A., Friedman, T. M., Korngold, R., Noelle, R. J. & Blazar, B. R. 2002a Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 99, 4601-4609. (doi:10.1182/blood.V99.12.4601.)
197. Taylor, P. A., Lees, C. J. & Blazar, B. R. 2002b The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499. (doi:10.1182/blood. V99.10.3493.)
198. Taylor, P. A., Panoskaltsis-Mortari, A., Freeman, G. J., Sharpe, A. H., Noelle, R. J., Rudensky, A. Y., Mak, T. W., Serody, J. S. & Blazar, B. R. 2004a Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells downregulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 105, 3372-3380. (doi:10.1182/blood-2004- 10-3869.)
199. Taylor, P. A., Panoskaltsis-Mortari, A., Swedin, J. M., Lucas, P. J., Gress, R. E., Levine, B. L., June, C. H., Serody, J. S. & Blazar, B. R. 2004b L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104, 3804-3812. (doi:10.1182/blood-2004-05-1850.)
200. Telford, W. G., Nam, S. Y., Podack, E. R. & Miller, R. A. 1997 CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol. 182, 125-136. (doi:10.1006/cimm.1997.1228.)
201. Tesciuba, A. G. et al. 2001 Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J. Immunol. 167, 1996-2003.
202. Teshima, T., Ordemann, R., Reddy, P., Gagin, S., Liu, C., Cooke, K. R. & Ferrara, J. L. 2002a Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat. Med. 8, 575-581. (doi:10.1038/nm0602-575.)
203. Teshima, T., Reddy, P., Lowler, K. P., KuKuruga, M. A., Liu, C., Cooke, K. R. & Ferrara, J. L. 2002b Flt3 ligand therapy for recipients of allogeneic bone marrow trans-plants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease. Blood 99, 1825-1832. (doi:10.1182/blood.V99.5.1825.)
204. Thornton, A. M. & Shevach, E. M. 1998 CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287-296. (doi:10.1084/jem.188.2.287.)
205. Thornton, A. M. & Shevach, E. M. 2000 Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190.
206. Trenado, A., Charlotte, F., Fisson, S., Yagello, M., Klatzmann, D., Salomon, B. L. & Cohen, J. L. 2003 Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 112, 1688-1696. (doi:10.1172/JCI200317702.)
207. Tse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C. & Guinan, E. C. 2003 Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389-397. (doi:10.1097/01.TP.0000045055.63901.A9.)
208. Tseng, S. Y. et al. 2001 B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839-846. (doi:10.1084/jem.193.7.839.)
209. Tsukada, N., Akiba, H., Kobata, T., Aizawa, Y., Yagita, H. & Okumura, K. 2000 Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 95, 2434-2439.
210. Uckun, F. M., Roers, B. A., Waurzyniak, B., Liu, X. P. & Cetkovic-Cvrlje, M. 2002 Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 99, 4192-4199. (doi:10.1182/blood.V99.11.4192.)
211. Urbano-Ispizua, A. et al. 2002 Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 29, 639-646. (doi:10.1038/sj.bmt.1703535.)
212. Vibhakar, R., Juan, G., Traganos, F., Darzynkiewicz, Z. & Finger, L. R. 1997 Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp. Cell Res. 232, 25-28. (doi:10.1006/excr.1997.3493.)
213. Vivier, E. & Daeron, M. 1997 Immunoreceptor tyrosine-based inhibition motifs. Immunol. Today 18, 286-291. (doi:10.1016/S0167-5699(97)80025-4.)
214. Wall, D. & Sheehan, K. 1994 The role of tumor necrosis factor and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation 57, 273-279.
215. Wang, S., Zhu, G., Chapoval, A. I., Dong, H., Tamada, K., Ni, J. & Chen, L. 2000 Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 96, 2808-2813.
216. Wang, J. W., Howson, J. M., Ghansah, T., Desponts, C., Ninos, J. M., May, S. L., Nguyen, K. H., Toyama-Sorimachi, N. & Kerr, W. G. 2002 Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 295, 2094-2097. (doi:10.1126/science.1068438.)
217. Weatherill, A. R., Maxwell, J. R., Takahashi, C., Weinberg, A. D. & Vella, A. T. 2001 OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo. Cell Immunol. 209, 63-75. (doi:10.1006/cimm.2001.1783.)
218. Weinberg, A. D. 1998 Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease. Mol. Med. Today 4, 76-83. (doi:10.1016/S1357-4310(97)01181-7.)
219. Weinberg, A. D. 2002 OX40: targeted immunotherapy - implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 23, 102-109. (doi:10.1016/S1471-4906(01)02127-5.)
220. Weinberg, A. D. et al. 2000 Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164, 2160-2169.
221. Welniak, L. A., Wang, Z., Sun, K., Kuziel, W., Anver, M. R., Blazar, B. R. & Murphy, W. J. 2004 An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Exp. Hematol. 32, 318-324. (doi:10.1016/j.exphem.2003.12.003.)
222. Welniak et al. Submitted. Peyer's patches are not required for acute graft-versus-host disease after murine allogeneic bone marrow transplantation. Blood.
223. Wiley, S. R., Goodwin, R. G. & Smith, C. A. 1996 Reverse signaling via CD30 ligand. J. Immunol. 157, 3635-3639.
224. Williams, M. A. et al. 2001 Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance. J. Immunol. 167, 4987-4995.
225. Wysocki, C. A., Burkett, S. B., Panoskaltsis-Mortari, A., Kirby, S. L., Luster, A. D., McKinnon, K., Blazar, B. R. & Serody, J. S. 2004 Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J. Immunol. 173, 845-854.
226. Wysocki, C. A., Panoskaltsis-Mortari, A., Blazar, B. R. & Serody, J. S. 2005 Leukocyte migration and graft-versus-host disease. Blood 105, 4191-4199. (doi:10.1182/blood-2004-12-4726.)
227. Yoshinaga, S. K. et al. 1999 T-cell co-stimulation through B7RP-1 and ICOS. Nature 402, 827-832. (doi:10.1038/45582.)
228. Yoshinaga, S. K. et al. 2000 Characterization of a new human B7-related protein: B7RP-1 is the ligand to the costimulatory protein ICOS. Int. Immunol. 12, 1439-1447. (doi:10.1093/intimm/12.10.1439.)
229. Yu, X. Z., Martin, P. J. & Anasetti, C. 1998 Role of CD28 in acute graft-versus-host disease. Blood 92, 2963-2970.
230. Yu, X. Z., Bidwell, S., Martin, P. J. & Anasetti, C. 1999 Visualization, fate, and pathogenicity of antigen-specific CD8+ T cells in the graft-versus-host reaction. J. Immunol. 163, 4780-4787.
231. Yu, X. Z., Bidwell, S. J., Martin, P. J. & Anasetti, C. 2000 CD28-specific antibody prevents graft-versus-host disease in mice. J. Immunol. 164, 4564-4568.
232. Zeller, J. C., Panoskaltsis-Mortari, A., Murphy, W. J., Ruscetti, F. W., Narula, S., Roncarolo, M. G. & Blazar, B. R. 1999 Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J. Immunol. 163, 3684-3691.
233. Zhang, Y., Shlomchik, W. D., Joe, G., Louboutin, J. P., Zhu, J., Rivera, A., Giannola, D. & Emerson, S. G. 2002 APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J. Immunol. 169, 7111-7118.
234. Zhou, D. et al. 2004 Lysosomal glycosphingolipid recognition by NKT cells. Science 306, 1786-1789. (doi:10.1126/science.1103440.)